Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches for MM — Dr Ajay Nooka CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 1: Optimizing the Current Management of Multiple Myeloma (MM) — Dr Joseph Mikhael CME information and select publications

Featuring perspectives from Drs Joseph Mikhael and Ajay Nooka, including the following topics: Introduction (0:00) Front-Line Treatment; Autologous Stem Cell Transplant (11:36) Use of Anti-CD38 Antibodies (29:36) CAR T-Cell Therapy (38:16) Treatment with Bispecific Antibodies (48:59) Other Treatments for Relapsed/Refractory Disease (56:07) CME information and select publications

Featuring perspectives from Drs Erica Mayer and Ruth O'Regan, including the following topics: Pregnancy during adjuvant endocrine therapy; fertility issues (0:00) Genomic biomarkers in the adjuvant setting (16:28) CDK4/6 inhibitors in metastatic disease (31:58) Adjuvant use of CDK4/6 inhibitors (47:42) Novel agents in metastatic disease (1:14:26) CME information and select publications

Featuring a slide presentation and related discussion from Professor Giuseppe Curigliano, including the following topics: Recent data with targeted therapies for patients with HER2-positive metastatic breast cancer (0:00) Case: A woman in her early 40s with a new right breast tumor 10 years after adjuvant radiation and endocrine therapy (17:17) Case: A woman in her mid 20s with a family history of breast cancer presenting with a lump in her left breast (26:34) CME information and select publications

Featuring an interview with Professor Giuseppe Curigliano, including the following topics: Vision for treating and curing HER2-positive metastatic breast cancer (mBC) in the future (0:00) Optimal treatment of HER2-positive mBC with brain metastases (7:42) Screening for and management of T-DXd-related interstitial lung disease (17:32) Gastric toxicities associated with the tucatinib/trastuzumab/capecitabine regimen and with T-DXd; differences in the toxicity profiles of these therapies between patients with HER2-positive and HER2-low breast cancer (23:50) Approach to endocrine therapy for triple-positive disease; emerging data with the AKT inhibitor capivasertib (28:43) Case: A woman in her mid 40s with a family history of breast cancer and upper limb soft tissue sarcoma who presents with a right breast lump and axillary adenopathy on self-examination (35:44) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 2: Therapeutic Approaches for Patients with Other Actionable Genomic Alterations — Dr Gregory Riely CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 1: Management of Non-Small Cell Lung Cancer with an EGFR, ALK or ROS1 Abnormality — Dr Zofia Piotrowska CME information and select publications

Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, including the following topics: Introduction: What Is Targeted Therapy? (0:00) EGFR-Activating Mutations (12:23) EGFR Exon 20 Insertion Mutations (27:54) ALK and ROS1 Rearrangements (31:31) HER2 Mutations (36:17) NRG1 Fusions (45:39) RET Fusions (49:07) MET Exon 14 Mutations (53:10) KRAS G12C Mutations (56:01) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 2: Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Deborah Stephens CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 1: Optimizing the First-Line Management of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Dr Jennifer Brown CME information and select publications

Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, including the following topics: Introduction: First-Line Treatment of Chronic Lymphocytic Leukemia (0:00) Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax; Venetoclax Consolidation (36:57) Noncovalent BTK Inhibitors; Pirtobrutinib (42:59) CAR T-Cell Therapy; Lisocabtagene Maraleucel (51:26) Richter's Transformation (56:31) CME information and select publications

Featuring perspectives from Dr Shaji Kumar, including the following topics: Introduction (0:00) Case: A woman in her early 70s with standard-risk newly diagnosed multiple myeloma (NDMM), "borderline transplant-eligible," receiving daratumumab-RVd, with transportation limitations and missed treatments — Neil Morganstein, MD (11:50) Case: A woman in her early 50s with Stage III, high-risk NDMM (1q21+), multiple bone lesions and acute renal impairment after RVd and transplant, now on the DRAMMATIC trial — Vignesh Narayanan, MD (24:43) Cases: A man in his early 60s with relapsed t(11;14) multiple myeloma (MM) and renal failure after RVd and ASCT, now on venetoclax/bortezomib/dexamethasone and a woman in her mid 50s with high-risk t(11;14) smoldering MM — Amany R Keruakous, MD, MS and Hans Lee, MD (32:59) Case: A man in his late 70s with transplant-ineligible NDMM who received daratumumab with lenalidomide/dexamethasone but discontinued daratumumab because of a severe rash — Yanjun Ma, MD (41:32) Case: A man in his mid 80s with a history of non-muscle-invasive bladder cancer, now with multiregimen-refractory MM and biochemical disease progression — Spencer Henick Bachow, MD (45:49) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 2: Metastatic Breast Cancer — Dr Joyce O'Shaughnessy CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 1: Localized Breast Cancer — Professor Peter Schmid CME information and select publications

Featuring perspectives from Dr Joyce O'Shaughnessy and Prof Peter Schmid, including the following topics: Introduction: POSITIVE Trial — Temporary Interruption of Endocrine Therapy for Pregnancy (0:00) Metastatic Breast Cancer — Dr O'Shaughnessy (7:44) Localized Breast Cancer — Prof Schmid (41:25) CME information and select publications

Featuring perspectives from Drs Courtney DiNardo and Mark Levis, including the following topics: Introduction (0:00) Case: A man in his early 80s with newly diagnosed acute myeloid leukemia (AML) with significant comorbidities receives decitabine/venetoclax — Rebecca L Olin, MD, MSCE (7:36) Cases: A man in his mid 50s after 7 + 3 and allogeneic stem cell transplantation (SCT) presents with myeloid sarcoma; a man in his late 70s after 7 + 3 and allogeneic SCT presents with myeloid sarcoma — Spencer H Bachow, MD and Ranju Gupta, MD (12:16) Case: A man in his late 30s with core binding factor AML after induction CLAG-M with gemtuzumab ozogamicin followed by high-dose cytarabine x 4 — Anna Halpern, MD (18:10) Case: A woman in her mid 60s with newly diagnosed del(5q) AML with monocytic differentiation and multiple mutations (GATA2, BCOR, NF1 and RUNX1) receives azacitidine and venetoclax — Bhavana (Tina) Bhatnagar, DO (31:05) Selection of Therapy for Patients with AML (35:20) Cases: A man in his early 50s with therapy-related AML with an MLL mutation who receives CPX-351; a man in his early 70s with secondary AML with an IDH mutation — Amany R Keruakous, MD, MS and Priya Rudolph, MD, PhD (41:42) Case: A man in his early 70s with recurrent AML with an IDH2 mutation receives enasidenib and develops differentiation syndrome/disease progression — Dr Halpern (50:00) CME information and select publications

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 1: Selection of Therapy for Older and Younger Patients with Acute Myeloid Leukemia (AML) — Dr Courtney DiNardo CME information and select publications

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment of AML with Targetable Mutations — Dr Andrew Wei CME information and select publications

Featuring an interview with Dr Manish Shah, including the following topics: Biologic rationale for targeting PD-1/PD-L1 in upper GI cancers (0:00) Management of HER2-positive gastric cancers (6:38) Activity and tolerability of therapies targeting claudin 18.2 for patients with GI malignancies (15:48) CME information and select publications

Featuring an interview with Dr Manish Shah, including the following topics: Role of targeted and immunotherapy regimens for upper GI cancers (0:00) Future of CAR T-cell therapy for patients with gastric cancer (11:26) Case: A man in his mid 60s with HER2-positive gastroesophageal adenocarcinoma (15:59) Case: A woman in her mid 70s with newly diagnosed HER2-negative, pMMR gastric cancer (29:57) Case: A man in his mid 50s with dMMR, HER2-negative gastric cancer (37:32) CME information and select publications

Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics: Front-Line Treatment of Multiple Myeloma (MM) Introduction (0:00) Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49) Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05) Dr Orlowski presentation (15:45) Integration of Novel Therapies into the Management of Relapsed/Refractory MM Cases: A transplant-eligible man in his late 60s with well-controlled HIV-1 and standard-risk NDMM and a man in his late 60s with high-risk, t(4;14) multiregimen-refractory MM with travel limitations who receives belantamab mafodotin — Neil Morganstein, MD and Syed Farhan Zafar, MD (29:19) Cases: A woman in her early 70s who receives daratumumab, bortezomib and dexamethasone for relapsed MM 6 years after RVd followed by autologous stem cell transplant and maintenance bortezomib, and a man in his mid 50s with NDMM who received RVd followed by maintenance lenalidomide, which was discontinued by the patient after 1 year — Henna Malik, MD and Dr Rupard (35:50) Dr Fonseca presentation (41:57) Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM Case: A man in his early 70s with NDMM who receives induction daratumumab/RVd — Spencer H Bachow, MD (52:27) Cases: A woman in her early 60s with relapsed MM and pathologic fractures who received induction daratumumab/Rd and palliative radiation therapy for bone disease, and a woman in her mid 70s with refractory MM 6 months after induction daratumumab/RVd lite — Dr Bhatnagar and Kimberly Ku, MD (57:00) Dr Raje presentation (1:01:12) Bispecific Antibodies in the Treatment of MM Case: A man in his early 70s with t(4;14) NDMM who initiates RVd, which is put on hold to treat severe depression — Warren S Brenner, MD (1:14:38) Case: A woman in her mid 70s with multiregimen-refractory del(17p) MM who is considered for BCMA-directed therapy — Dr Bachow (1:16:28) Dr Berdeja presentation (1:22:18) Other Investigational Novel Agents for MM Case: A woman in her mid 80s with congestive heart failure and t(4;14), t(11;14) and t(14;16) MM who receives dose-reduced RVd and develops chalazion eye toxicity — Jennifer L Dallas, MD (1:36:23) Dr Lonial presentation (1:39:34) CME information and select publications

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics: Diffuse Large B-Cell Lymphoma (DLBCL) Introduction (0:00) Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36) Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Stage IE DLBCL and a man in his early 80s with Stage IIIB DLBCL, GCB type and LVEF 35% to 40% due to prior myocardial infarction and coronary artery disease — Bhavana (Tina) Bhatnagar, DO and Yanjun Ma, MD (7:10) Dr Friedberg presentation (11:54) Follicular Lymphoma Case: A man in his late 60s with progressive Grade I/II follicular lymphoma after observation for many years — Neil Morganstein, MD (29:07) Case: A woman in her early 60s with Grade II follicular lymphoma who received bendamustine/rituximab and maintenance rituximab — Jennifer L Dallas, MD (33:11) Dr Nastoupil presentation (38:36) Hodgkin Lymphoma Case: A woman in her early 80s with newly diagnosed classical Hodgkin lymphoma — Kapisthalam (KS) Kumar, MD(51:21) Cases: A woman in her late 30s with newly diagnosed classical Hodgkin lymphoma and a man in his early 60s with newly diagnosed Stage IV classical Hodgkin lymphoma who receives brentuximab/vedotin with AVD (doxorubicin/vinblastine/dacarbazine) — Susmitha Apuri, MD and Amany R Keruakous, MD, MS (55:21) Dr Smith presentation (1:10:17) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma Cases: A man in his late 50s who presents with a large cecal mass and mesenteric adenopathy and is diagnosed with "double hit" DLBCL and a woman in her early 70s with DLBCL treated with R-CHOP, now with progressive disease 6 months later — Vignesh Narayanan, MD and Rahul Gosain, MD (1:14:56) Case: A woman in her early 70s with rapid relapse after R-CHOP then R-ICE (rituximab/ifosfamide/carboplatin/etoposide) and ASCT who achieves a complete response with CAR T-cell therapy but experiences significant pancytopenias — John Yang, MD (1:22:10) Dr Maloney presentation (1:25:24) Mantle Cell Lymphoma (MCL) Case: A man in his late 70s with high-risk relapsed MCL after BR and maintenance rituximab x 3 years — Raman Sood, MD (1:39:10) Case: A man in his mid 80s who received prior treatment for prostate cancer and presents with low-volume indolent MCL with a TP53 mutation — Spencer H Bachow, MD (1:42:47) Dr Kahl presentation (1:45:29) CME information and select publications

Featuring an interview with Dr Scott Tagawa, including the following topics: Sequencing therapies for patients with metastatic urothelial bladder cancer (UBC) (0:00) Case: A man in his mid 80s with UBC with multiple lung and lymph node metastases (4:55) Case: A woman in her mid 80s with metastatic UBC who is undergoing treatment with erdafitinib (46:21) Case: A man in his mid 60s with FGFR-altered metastatic UBC (49:45) CME information and select publications

Featuring a slide presentation and related discussion from Dr Scott Tagawa, including the following topics: Managing patients with FGFR-altered urothelial bladder cancer (UBC) (0:00) Antibody-drug conjugates as treatment for metastatic UBC (10:22) Strategies for using systemic therapies to treat metastatic UBC (27:31) CME information and select publications

Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer Introduction (0:00) Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) – 21-gene Recurrence Score® 22 — Alan B Astrow, MD (3:39) Case: A premenopausal woman in her mid 30s with 3.6-cm, ER/PR-positive, HER2-low (IHC 1+), sentinel node-positive (4/4) multifocal IDC after bilateral mastectomies, adjuvant AC-T and ovarian function suppression (OFS)/aromatase inhibitor, Ki67 50% — Laila Agrawal, MD (9:40) Dr Goetz presentation (19:43) Optimizing the Management of Localized ER-Positive Breast Cancer Case: A woman in her early 40s with 5.5-cm, ER/PR-positive, HER2-negative, node-positive (20/21) IDC after bilateral mastectomies, bilateral salpingo-oophorectomy, adjuvant AC-T and initiation of letrozole/abemaciclib, Ki-67 3% — Susmitha Apuri, MD (32:22) Case: A woman in her mid 50s with de novo ER-positive, PR-negative, HER2-negative ulcerated breast cancer with pulmonary and extensive spinal metastases — Jennifer L Dallas, MD (40:45) Dr Kaklamani presentation (45:32) Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 50s with ER/PR-positive, HER2-low mBC with a PI3KCA mutation who experiences a dramatic response to rechallenge with fulvestrant and a CDK4/6i (abemaciclib); now with progression and cytopenias — Kapisthalam (KS) Kumar, MD (59:07) Dr Kalinsky presentation (1:09:53) Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer Case: A premenopausal woman in her late 30s with ER/PR-positive, HER2-low (IHC 1+) IDC after adjuvant tamoxifen and OFS x 5 years, now with bone and liver metastases — Dr Agrawal (1:19:45) Dr Bardia presentation (1:24:29) Novel Strategies Under Investigation for Patients with HR-Positive mBC Case: A woman in her early 90s with ER/PR-positive, HER2-low (IHC 1+) mBC and progressive disease on multiple lines of endocrine and chemotherapy receives T-DXd — Dr Astrow (1:38:44) Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 2+) mBC who has received fulvestrant/abemaciclib, now receiving exemestane/everolimus – ESR1 and PIK3CA mutations — Dr Dallas (1:44:15) Dr Rugo presentation (1:49:58) CME information and select publications

Featuring perspectives from Drs Alexey Danilov, Matthew Davids, Lindsey Roeker, Philip Thompson and Prof Dr Arnon Kater, including the following topics: Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Introduction (0:00) Cases: A man in his early 90s with Rai Stage 0 CLL who underwent surveillance x 5 years and now develops cytopenias and transfusion-dependent anemia, and a woman in her late 60s with IGHV-unmutated CLL who develops night sweats, rapid doubling time of ALC — Bhavana (Tina) Bhatnagar, DO and Jennifer L Dallas, MD (3:18) Case: A man in his mid 50s with relapsed CLL after ibrutinib x 5 years now with disease progression — Amany R Keruakous, MD, MS (9:11) Dr Danilov presentation (16:47) Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL Case: A man in his late 70s with IGHV-unmutated CLL under observation for many years who develops B symptoms, cytopenias and lymphadenopathy — Henna Malik, MD (32:15) Prof Kater presentation (37:18) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations Case: A man in his early 70s with multiple musculoskeletal comorbidities and transportation limitations develops symptomatic IGHV-mutated CLL with cytopenias — Syed F Zafar, MD (51:08) Cases: A man in his mid 50s with del(17p) CLL and significant lymphadenopathy and B symptoms who receives acalabrutinib and a woman in her early 70s with IGHV-mutated CLL and a complex karyotype — Dr Keruakous and Spencer H Bachow, MD (55:10) Dr Davids presentation (1:03:01) Selection and Sequencing of Available Therapies for Relapsed/Refractory Disease Case: A man in his mid 70s with relapsed del(17p) CLL after ibrutinib with multiple chronic low-grade toxicities — Dr Bhatnagar (1:16:23) Dr Thompson presentation (1:20:56) Promising Investigational Agents and Strategies Case: A woman in her late 70s with CLL (p53, 11q, 13q mutations), disease progression on ibrutinib and a BTK C481S mutation detected on repeat testing — Dr Bachow (1:39:09) Case: A man in his late 70s who develops Richter's transformation while receiving obinutuzumab/venetoclax for CLL — Justin Peter Favaro, MD, PhD (1:43:12) Dr Roeker presentation (1:48:29) CME information and select publications

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31) Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05) Dr Tolaney presentation (18:44) Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 60s with an 8-cm, ER-negative, PR-positive, HER2-positive IDC and positive nodes bilaterally after neoadjuvant TCHP and bilateral mastectomies with no residual disease — Henna Malik, MD (31:12) Case: A woman in her late 50s with Stage IIIA, ER/PR-negative, HER2-positive, node-positive IDC with residual disease after neoadjuvant TCHP and mastectomy — Laila Agrawal, MD ()35:29 Dr Krop presentation (42:56) Management of HER2-Positive Breast Cancer with CNS Metastases Case: A woman in her early 90s with "mild" dementia and ER/PR-negative, HER2 IHC 1+ IDC with symptomatic chest wall recurrence after neoadjuvant paclitaxel/trastuzumab and lumpectomy — Alan B Astrow, MD (54:54) Case: A woman in her late 40s with a triple-positive multifocal IDC with a gBRCA2 mutation and HER2-negative axillary nodes after neoadjuvant TCHP and bilateral mastectomies with significant response in the breast but 49 positive nodes — Zanetta S Lamar, MD (1:00:01) Dr Hamilton presentation (1:06:51) Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer Cases: A premenopausal woman in her late 30s with a triple-positive IDC who develops brain metastases while receiving THP; A woman in her late 60s with an ER/PR-negative, HER2-positive IDC who develops brain metastases after first-line THP and second-line T-DM1 — Kelly Yap, MD & Rohit Gosain, MD (1:20:46) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive mBC treated with paclitaxel/trastuzumab, then T-DXd on progression — Joanna Metzner-Sadurski, MD (1:29:40) Dr Modi presentation (1:40:51) Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy Case: A woman in her early 60s with recurrent triple-positive mBC whose disease converts to HER2-negative, PIK3CA-positive at the time of progression — Dhatri Kodali, MD (2:01:10) Dr Hurvitz presentation (2:05:08) CME information and select publications

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics: Keys to evaluating genetics in patients with ovarian cancer (0:00) Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35) Current status of PARP inhibitor use in the care of patients with ovarian cancer (18:45) Ongoing studies evaluating the combination of PARP and immune checkpoint inhibitors (24:37) CME information and select publications

Featuring perspectives from Dr Thomas Herzog, including the following topics: Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00) Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13) Sequential use of PARPi for patients with advanced ovarian cancer (16:56) Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06) Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22) Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02) CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 2: TROP2 and Other Investigational Targets for ADCs in Advanced NSCLC — Dr Alexander Spira CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 1: Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC) — Dr Helena Yu CME information and select publications

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics: Introduction What is an antibody-drug conjugate? (0:00) "HER2-Positive" Non-Small Cell Lung Cancer (NSCLC) Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42) Targeting HER3 in NSCLC Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23) TROP2-Directed Treatment Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57) Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32) Novel Agents Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15) CME information and select publications

Featuring perspectives from Dr S Vincent Rajkumar, including the following topics: Introduction: Requiem for Belantamab Mafodotin? Dawn of a New Era (0:00) Case: A man in his early 70s with multiregimen-refractory multiple myeloma (MM) receives idecabtagene vicleucel with Grade 1 cytokine release syndrome and persistent cytopenias — Jesús G Berdeja, MD (16:12) Case: A man in his mid 60s with multiregimen-refractory MM receives idecabtagene vicleucel with a 20-month response — Dr Berdeja (25:19) Case: A man in his late 50s with multiregimen-refractory MM received idecabtagene vicleucel in 2020 and is currently in complete remission — Natalie S Callander, MD (31:11) Case: A man in his early 60s with multiregimen-refractory MM receives the novel bispecific antibody WVT078 on a clinical trial — Dr Callander (41:02) Case: A man in his mid 70s with multiregimen-refractory MM receives teclistamab on a clinical trial — Dr Berdeja (51:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Omid Hamid, including the following topics: Current evolution in the care of patients with metastatic melanoma (0:00) Novel immunotherapeutic strategies for patients with untreated metastatic melanoma (1:47) Efficacy and safety of novel agents and combination treatments for patients with previously treated metastatic melanoma (16:28) Future directions in the care of patients with metastatic melanoma (25:13) CME information and select publications

Featuring an interview with Dr Omid Hamid, including the following topics: First-line treatment of metastatic melanoma (0:00) Triplet therapy for patients with BRAF-mutated metastatic melanoma (7:27) Case: A man in his mid 60s with previously untreated BRAF wild-type metastatic melanoma (15:44) Novel therapeutic strategies for patients with newly diagnosed melanoma (21:02) Immunotherapy strategies for second-line treatment of metastatic melanoma (29:25) Case: A man in his mid 40s with BRAF-mutated melanoma who experiences disease progression after treatment with ipilimumab and nivolumab (37:16) CME information and select publications

Featuring a slide presentation and related discussion from Dr Eric Sherman, including the following topics: Incidence and mortality of thyroid cancer and the thyroid cancer treatment pyramid (0:00) Available and emerging data with targeted therapies for thyroid cancer (9:01) Optimal genomic screening and selection of treatment for medullary thyroid cancer (26:58) CME information and select publications

Featuring an interview with Dr Eric Sherman, including the following topics: Changes in the incidence, mortality, and management of thyroid cancer in the past 20 years (0:00) Clinical presentation and histologic characteristics of thyroid cancer; genomic alterations associated with each histology (5:55) Initial management of thyroid cancer; current role of surgery and radioactive iodine in treatment algorithms (14:56) Current and future role of tumor biomarkers in treatment selection; emerging role of liquid biopsies in anaplastic thyroid cancer (20:23) Incidence and optimal treatment of brain metastases in patients with thyroid cancer; biologic rationale for tyrosine kinase inhibitors (TKIs) targeting VEGF and BRAF in thyroid cancer (24:20) Safety and tolerability of sorafenib and lenvatinib; management of BRAF-mutated disease (34:49) Management of tumors in patients with RET alterations or NTRK fusions; therapies for medullary tumors (39:28) Case: A woman in her early 60s with metastatic papillary thyroid cancer; ongoing research combining TKIs and immunotherapy for anaplastic thyroid cancer (50:35) Case: A man in his early 40s presenting with severe diarrhea and metastatic medullary thyroid cancer (1:00:54) CME information and select publications

Featuring perspectives from Prof Karim Fizazi and Prof Stéphane Oudard, including the following topics: Introduction: Journal Club — Karim Fizazi, MD, PhD and Stéphane Oudard, MD, PhD (0:00) Case: A man in his late 50s with Gleason 7 prostate cancer after prostatectomy/radiation therapy/androgen deprivation therapy (ADT) experiences biochemical recurrence 2 years later (PSA 0.5; doubling time 9 months) — Philip L Brooks, MD (10:58) Case: A man in his early 70s with a pacemaker presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC) after cerebrovascular accident — Nasfat Shehadeh, MD (28:50) Case: A man in his late 40s with multiple medical comorbidities presents with de novo mHSPC (PSA 19.4) and responds to ADT/docetaxel — Gurveen Kaur, MD (47:00) Case: A man in his mid 60s with de novo mHSPC receives leuprolide, and PSA levels decrease from 865 ng/mL to 1.34 ng/mL — Joanna Metzner-Sadurski, MD (50:38) Case: A man in his late 50s with mHSPC receives leuprolide, experiences disease progression 1.5 years later and responds to abiraterone/prednisone but on liquid biopsy is found to have an AR T878 mutation — Niyati A Nathwani, MD (54:30) Case: A man in his mid 60s presents with de novo metastatic prostate cancer and experiences disease progression on ADT + docetaxel, now with progressive disease on abiraterone/prednisone; germline CHEK2 mutation — Syed F Zafar, MD (56:51) CME information and select publications

Featuring a slide presentation and related discussion from Dr Jeffrey Zonder, including the following topics: Overview of amyloid light chain (AL) amyloidosis (0:00) Case: An African American man in his late 70s with transthyretin amyloidosis (8:39) Staging and prognosis of AL amyloidosis (14:11) Evolution of the amyloidosis treatment paradigm (26:39) Case: A woman in her late 70s with relapsed lambda light chain amyloidosis (44:33) Emerging data with novel therapies for AL amyloidosis (47:38) Case: A man in his early 60s with relapsed lambda light chain amyloidosis (52:18) CME information and select publications

Featuring an interview with Dr Jeffrey Zonder, including the following topics: Biology and symptomology of primary amyloidosis (0:00) Staging and prognosis for patients with amyloid light chain (AL) amyloidosis (10:21) Supportive care for patients with advanced disease (16:25) Current amyloidosis treatment paradigm (21:49) Monoclonal antibody therapy for patients with AL amyloidosis (31:38) CME information and select publications

Featuring perspectives from Dr Daniel Pollyea, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35) Defining AML versus Myelodysplastic Syndromes (6:06) Case: A man in his early 80s presenting with cytopenias and AML (8:56) Oral Decitabine/Cedazuridine (18:15) Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43) HMA/Venetoclax for Younger Patients (39:56) Translational Biology of AML: New Agents and Treatment Strategies (44:08) Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48) Anti-CD47 Antibody Magrolimab (51:08) Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22) CME information and select publications

Featuring perspectives from Dr Paul Richardson, including the following topics: Introduction (0:00) Case: A man in his early 60s with newly diagnosed Stage II standard-risk multiple myeloma — Ranju Gupta, MD (29:31) Case: A woman in her early 70s with Stage IIIA multiple myeloma who receives lenalidomide/bortezomib/dexamethasone → autologous stem cell transplant (ASCT) and discontinues maintenance lenalidomide after 3 years — Erik Rupard, MD (34:16) Case: A woman in her early 70s with relapsed myeloma after tandem ASCT who receives cyclophosphamide/bortezomib/dexamethasone, achieves minimum residual disease negativity and is now on maintenance ixazomib — Zanetta S Lamar, MD (39:01) Case: A woman in her early 70s with triple-class refractory t(11;14) multiple myeloma — Hans Lee, MD (43:47) Case: A man in his mid 60s with high-risk relapsed multiple myeloma after carfilzomib/lenalidomide/dexamethasone (KRd) induction, ASCT, maintenance KRd and 2 additional lines of therapy — Muzaffar H Qazilbash, MD (46:05) Faculty Survey (52:29) Journal Club with Dr Richardson (60:57) CME information and select publications

Featuring a slide presentation and related discussion from Dr Ruben Mesa, including the following topics: Efficacy and safety of FDA-approved JAK inhibitors for the management of myelofibrosis (MF) (0:00) Emerging JAK inhibitors under Phase III evaluation for MF (6:59) Current guidelines and strategies for managing MF (13:53) Emerging data with novel agents and strategies for MF (17:31) Splenic response and symptomology in patients with MF (25:36) CME information and select publications

Featuring an interview with Dr Ruben Mesa, including the following topics: Managing myelofibrosis (MF) before the availability of ruxolitinib (0:00) Pathobiology and mutational profile of MF (7:33) Matching treatments to individual patients with MF (13:25) Case: A man in his early 70s with MF and worsening anemia (17:13) Case: A man in his late 60s initially diagnosed with polycythemia vera now with MF requiring therapy (23:15) Case: A woman in her mid 60s with MF that has a suboptimal response to first-line JAK inhibitor therapy (30:25) Efficacy and safety of novel agents and strategies for MF (35:40) CME information and select publications

Featuring perspectives from Drs Ursula Matulonis and Debra Richardson, including the following topics: PROLOGUE: Antibody-Drug Conjugates Across Oncology (0:00) Antibody-Drug Conjugates in Ovarian Cancer: Mirvetuximab Soravtansine (10:03) Antibody-Drug Conjugates in Ovarian Cancer: Upifitamab Rilsodotin (29:09) Tumor Treating Fields (41:35) PARP Inhibitor Update (47:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr Toni Choueiri, including the following topics: Evolution in the management of renal cell carcinoma (RCC) (0:00) Adjuvant therapy for intermediate- or high-risk RCC (1:52) Front-line therapy for patients with metastatic RCC (8:39) New agents for the treatment of relapsed or refractory RCC (16:24) Mechanism of action and efficacy of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (19:56) CME information and select publications

Featuring an interview with Dr Toni Choueiri, including the following topics: Case: A woman in her early 70s with a large kidney tumor and multiple pulmonary nodules (0:00) Case: A woman in her early 60s diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12:52) Approach to adjuvant treatment for RCC (16:14) Examining differences between PD-1 and PD-L1 inhibitors (20:09) Management of non-clear cell RCC (24:10) Challenges in identifying patients with RCC who are more likely to benefit from immune checkpoint inhibitors (28:22) Mechanisms of action of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (30:31) Future directions in the care of patients with RCC (36:24) CME information and select publications

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: Anti-PD-1 and PD-L1 Monotherapy for NSCLC — Dr Stephen Liu CME information and select publications

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Current Treatment Landscape for Non-Small Cell Lung Cancer (NSCLC) — Dr John Heymach CME information and select publications